Docket No. 126-PCT2-US

IN THE UNITED STATE PATENT AND TRADE MARK OFFICE

Applicant:

James Jaquith et al

Art unit:

Not yet assigned

Serial No:

PCT/CA2004/001484

Examiner:

Not yet assigned

Filed:

11 August 2004

Customer No:

45980

Title:

3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, and 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF

APOPTOSIS.

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, Virginia USA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This statement is being filed with the application. Applicants submit the enclosed PTO 1449 form identifying six (6) references. Under 35 USC § 120, this application relies on the earlier filing date of application serial number PCT-CA2004/001484 filed August 11 2004.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Respectfully submitted,

Date: January 30 2006.

Registration No: 55,978

Dr. Philip A. Swain c/o Aegera Therapeutics Inc 810 Chemin du Golf Nun's Island, Quebec Canada H3E 1A8

Telephone: (514) 288 - 4091 Ext: 353

Facsimile: (514) 288 - 9820

10/566752 IAP9 Rec'd PCT/PTO

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			Complete if Known		
		Application Number	PCT/CA2004/001484		
INFORMA	ATION DISCLOSURE	Filing Date	August 11 2004		
		First Named Inventor	James B. Jaquith		
	ENT BY APPLICANT	Art Unit			
(Use a	s many sheets as necessary)	Examiner Name			
Chast 1	of 2	Attorney Docket Number	126-PCT2-US		

	U. S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ	Number-Kind Code ^{2 (if known)}	ļ <u> </u>		rigules Appeal
		^{US-} 5,057,614	10-15-1991	Davis et al	
		US-			
1		US-			
		US-			
****		US-			
		US-			
-		US-			
		US-			
		US-	•		
		US-			
		US-		,	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		CA 2,409,355	11-22-2001	Fallis et al		
		WO 99/47518 A	09-23-1999	Hoffman-LaRoche		
		WO 98/04551 A	02-05-1998	Hoffman-LaRoche	-	
	ļ					
						L
]					

			·
1	Examiner	Date	
ı	Signature	Considered	Ì
Į			ł .

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
	Application Number	PCT/CA2004/001484	
INFORMATION DISCLOSURE	Filing Date	August 11 2004	
STATEMENT BY APPLICANT	First Named Inventor	James B. Jaquith	
(Use as many sheets as necessary)	Art Unit		
(use as many sneets as necessary)	Examiner Name		
Sheet 2 of 2	Attorney Docket Number	126-PCT2-US	

in a s	C:40	NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	DAVIS, P.D., et al. "Inhibitors of Proteinkinase C.I. 2,3-Bisarylmaleimides". Journal of Medicinal Chemistry, vol. 35, no. 1, 10 January 1992, pages 177-184.	
·	2	DAVIS, P.D., et al." A Mild Conversion of Maleic Anhydrides into Maleimides", Tetrahedron Letters, vol.31, no. 36, 1990, pages 5201-5204	
	*		
		·	
•			

Examiner	Date	
Signature	 Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: